<p>Incremental cost-effectiveness as a function of anemia treatment targets in persons with CKD stages 3–4.</p
Mean medical costs, numbers of subjects, and starting chronic dialysis in the subpopulations based o...
Objective: To determine whether Medicare's decision to cover routine administration of erythropoieti...
<p>Incremental cost-effectiveness ratios (ICER) over all scenarios (mean values).</p
Although major guidelines uniformly recommend iron supplementation and erythropoietin stimulating ag...
<p>Key parameters for probabilistic sensitivity analysis in the CKD Health Policy Model related to a...
<p>One-way sensitivity analyses of cost-effectiveness for different anemia treatment targets.</p
<p>Annualized anemia treatment decision flowchart assumed in the CKD Policy Model.</p
<p>The incremental cost-effectiveness ratio was calculated according to an increasing treatment comp...
<p>Incremental cost-effectiveness ratio for improved IMCI quality of care in a simulated cohort of 1...
<p>Incremental cost-effectiveness ratio in increasing order of total infection averted.</p
ABSTRACTObjectiveTo examine the economic impact of patients with anemia in selected diseases.Methods...
Anemia in Chronic Kidney Disease (CKD) is present in approximately 90% of patients with glomerular f...
Therapeutic management of incident patients with anemia of NDD-CKD during the first year after the i...
<p>Incremental Cost-Effectiveness Ratios for Treatment Duration and Heroin Use Outcomes at 6 Months....
<p>Analyses of incremental cost-effectiveness ratios (ICERs) based on age and risk groups.</p
Mean medical costs, numbers of subjects, and starting chronic dialysis in the subpopulations based o...
Objective: To determine whether Medicare's decision to cover routine administration of erythropoieti...
<p>Incremental cost-effectiveness ratios (ICER) over all scenarios (mean values).</p
Although major guidelines uniformly recommend iron supplementation and erythropoietin stimulating ag...
<p>Key parameters for probabilistic sensitivity analysis in the CKD Health Policy Model related to a...
<p>One-way sensitivity analyses of cost-effectiveness for different anemia treatment targets.</p
<p>Annualized anemia treatment decision flowchart assumed in the CKD Policy Model.</p
<p>The incremental cost-effectiveness ratio was calculated according to an increasing treatment comp...
<p>Incremental cost-effectiveness ratio for improved IMCI quality of care in a simulated cohort of 1...
<p>Incremental cost-effectiveness ratio in increasing order of total infection averted.</p
ABSTRACTObjectiveTo examine the economic impact of patients with anemia in selected diseases.Methods...
Anemia in Chronic Kidney Disease (CKD) is present in approximately 90% of patients with glomerular f...
Therapeutic management of incident patients with anemia of NDD-CKD during the first year after the i...
<p>Incremental Cost-Effectiveness Ratios for Treatment Duration and Heroin Use Outcomes at 6 Months....
<p>Analyses of incremental cost-effectiveness ratios (ICERs) based on age and risk groups.</p
Mean medical costs, numbers of subjects, and starting chronic dialysis in the subpopulations based o...
Objective: To determine whether Medicare's decision to cover routine administration of erythropoieti...
<p>Incremental cost-effectiveness ratios (ICER) over all scenarios (mean values).</p
DOI
Add to ORKG